- Home
- LBPH vs DMRC Comparison
LBPH vs DMRC Comparison
Compare LBPH & DMRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LBPH
- DMRC
- Stock Information
- Founded
- LBPH 2020
- DMRC 2008
- Country
- LBPH United States
- DMRC United States
- Employees
- LBPH N/A
- DMRC N/A
- Industry
- LBPH Biotechnology: Pharmaceutical Preparations
- DMRC EDP Services
- Sector
- LBPH Health Care
- DMRC Technology
- Exchange
- LBPH Nasdaq
- DMRC Nasdaq
- Market Cap
- LBPH 810.3M
- DMRC 734.8M
- IPO Year
- LBPH 2021
- DMRC N/A
- Fundamental
- Price
- LBPH $34.86
- DMRC $25.81
- Analyst Decision
- LBPH Strong Buy
- DMRC Buy
- Analyst Count
- LBPH 7
- DMRC 3
- Target Price
- LBPH $52.43
- DMRC $34.00
- AVG Volume (30 Days)
- LBPH 482.1K
- DMRC 114.0K
- Earning Date
- LBPH 10-31-2024
- DMRC 11-04-2024
- Dividend Yield
- LBPH N/A
- DMRC N/A
- EPS Growth
- LBPH N/A
- DMRC N/A
- EPS
- LBPH N/A
- DMRC N/A
- Revenue
- LBPH N/A
- DMRC $38,595,000.00
- Revenue This Year
- LBPH N/A
- DMRC $20.47
- Revenue Next Year
- LBPH N/A
- DMRC $22.05
- P/E Ratio
- LBPH N/A
- DMRC N/A
- Revenue Growth
- LBPH N/A
- DMRC 22.09
- 52 Week Low
- LBPH $3.60
- DMRC $21.00
- 52 Week High
- LBPH $40.48
- DMRC $43.43
- Technical
- Relative Strength Index (RSI)
- LBPH 50.51
- DMRC 38.50
- Support Level
- LBPH $32.78
- DMRC $26.92
- Resistance Level
- LBPH $37.29
- DMRC $29.33
- Average True Range (ATR)
- LBPH 2.47
- DMRC 1.15
- MACD
- LBPH -0.27
- DMRC -0.06
- Stochastic Oscillator
- LBPH 38.03
- DMRC 14.56
About LBPH Longboard Pharmaceuticals Inc.
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.
About DMRC Digimarc Corporation
Digimarc Corp is engaged in digital watermarking technologies. The Digimarc Illuminate platform is a distinctive software as a service (SaaS) cloud-based platform for digital connectivity that provides the tools for the application of digital watermarks and dynamic Quick Response (QR) codes, software (digital twins) that enables various systems and devices to interact with those data carriers, and a centralized platform for capturing insights about digital interactions and automating activities based on that information. The company generates revenue through commercial and government applications of its technology. The company derives its revenue from software development services, subscriptions for products and related services, and licensing of patents.